Therefore, targeting glutaminolysis using glutaminase inhibitors presents a promising therapeutic approach for aggressive subtypes of lung cancer with mutations in KEAP1/NRF2 (Romero et al. 2017). Here, KEAP1 is linked to lung cancer.